| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Mark M Yore, Ismail Syed, Pedro M Moraes-Vieira, Tejia Zhang, Mark A Herman, Edwin A Homan, Rajesh T Patel, Jennifer Lee, Shili Chen, Odile D Peroni, Abha S Dhaneshwar, Ann Hammarstedt, Ulf Smith, Timothy E McGraw, Alan Saghatelian, Barbara B Kah. Discovery of a class of endogenous mammalian lipids with anti-diabetic and anti-inflammatory effects. Cell. vol 159. issue 2. 2015-03-06. PMID:25303528. |
pahsa administration in mice lowers ambient glycemia and improves glucose tolerance while stimulating glp-1 and insulin secretion. |
2015-03-06 |
2023-08-13 |
mouse |
| Conrad Eng, Caroline K Kramer, Bernard Zinman, Ravi Retnakara. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet (London, England). vol 384. issue 9961. 2015-03-03. PMID:25220191. |
combination treatment with a glucagon-like peptide-1 (glp-1) agonist and basal insulin has been proposed as a treatment strategy for type 2 diabetes that could provide robust glucose-lowering capability with low risk of hypoglycaemia or weight gain. |
2015-03-03 |
2023-08-13 |
Not clear |
| Laura A Young, John B Bus. GLP-1 receptor agonists and basal insulin in type 2 diabetes. Lancet (London, England). vol 384. issue 9961. 2015-03-03. PMID:25220193. |
glp-1 receptor agonists and basal insulin in type 2 diabetes. |
2015-03-03 |
2023-08-13 |
Not clear |
| Gabriella A Heruc, Michael Horowitz, Carolyn F Deacon, Christine Feinle-Bisset, Christopher K Rayner, Natalie Luscombe-Marsh, Tanya J Littl. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males. American journal of physiology. Endocrinology and metabolism. vol 307. issue 9. 2015-02-26. PMID:25231186. |
blood glucose, plasma insulin, glucagon, active glp-1, and gip and peptide yy (pyy)-(3-36) concentrations; resting energy expenditure; and energy intake at a subsequent buffet meal (time = 120-150 min) were quantified. |
2015-02-26 |
2023-08-13 |
Not clear |
| Gabriella A Heruc, Michael Horowitz, Carolyn F Deacon, Christine Feinle-Bisset, Christopher K Rayner, Natalie Luscombe-Marsh, Tanya J Littl. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males. American journal of physiology. Endocrinology and metabolism. vol 307. issue 9. 2015-02-26. PMID:25231186. |
this was associated with increased insulin (p: 15,964 ± 1,193 vs. v: 18,243 ± 1,257 pmol·l⁻¹·min⁻¹, p < 0.05), reduced glucagon (p: 1,008 ± 52 vs. v: 902 ± 46 pmol·l⁻¹·min⁻¹, p < 0.05), enhanced active glp-1 (p: 294 ± 40 vs. v: 694 ± 78 pmol·l⁻¹·min⁻¹) and gip (p: 2,748 ± 77 vs. v: 4,256 ± 157 pmol·l⁻¹·min⁻¹), and reduced pyy-(3-36) (p: 9,527 ± 754 vs. v: 4,469 ± 431 pm/min) concentrations compared with placebo (p < 0.05, for all). |
2015-02-26 |
2023-08-13 |
Not clear |
| Gabriella A Heruc, Michael Horowitz, Carolyn F Deacon, Christine Feinle-Bisset, Christopher K Rayner, Natalie Luscombe-Marsh, Tanya J Littl. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males. American journal of physiology. Endocrinology and metabolism. vol 307. issue 9. 2015-02-26. PMID:25231186. |
vildagliptin 1) modulates the effects of intraduodenal fat to enhance active glp-1 and gip, stimulate insulin, and suppress glucagon, thereby reducing glycemia and 2) increases energy expenditure. |
2015-02-26 |
2023-08-13 |
Not clear |
| Antonella Napolitano, Sam Miller, Andrew W Nicholls, David Baker, Stephanie Van Horn, Elizabeth Thomas, Deepak Rajpal, Aaron Spivak, James R Brown, Derek J Nune. Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. PloS one. vol 9. issue 7. 2015-02-21. PMID:24988476. |
at these timepoints we profiled glucose, insulin, gut hormones (glucagon-like peptide-1 (glp-1), peptide tyrosine-tyrosine (pyy) and glucose-dependent insulinotropic peptide (gip) and bile acids in blood, as well as duodenal and faecal bile acids and gut microbiota. |
2015-02-21 |
2023-08-13 |
human |
| Hale M Tasyurek, Hasan Ali Altunbas, Mustafa Kemal Balci, Salih Sanliogl. Incretins: their physiology and application in the treatment of diabetes mellitus. Diabetes/metabolism research and reviews. vol 30. issue 5. 2015-02-19. PMID:24989141. |
because glucagon-like peptide-1 (glp-1) is an incretin hormone with various anti-diabetic actions including stimulation of glucose-induced insulin secretion, inhibition of glucagon secretion, hepatic glucose production and gastric emptying, it has been evaluated as a novel therapeutic agent for the treatment of type 2 diabetes mellitus (t2dm). |
2015-02-19 |
2023-08-13 |
Not clear |
| Aubrey R Tiernan, Julie A Champion, Athanassios Sambani. Trichostatin A affects the secretion pathways of beta and intestinal endocrine cells. Experimental cell research. vol 330. issue 1. 2015-02-19. PMID:25305500. |
the aims of the present study were to investigate the effect of hdaci on insulin secretion from β-cells, glp-1 secretion from l-cells, and recombinant insulin secretion from engineered l-cells. |
2015-02-19 |
2023-08-13 |
Not clear |
| Aubrey R Tiernan, Julie A Champion, Athanassios Sambani. Trichostatin A affects the secretion pathways of beta and intestinal endocrine cells. Experimental cell research. vol 330. issue 1. 2015-02-19. PMID:25305500. |
effects on insulin or glp-1 mrna, intracellular protein content, processing efficiency, and secretion were measured by real-time pcr, elisa, and radioimmunoassay. |
2015-02-19 |
2023-08-13 |
Not clear |
| Maria Hauge, Marie A Vestmar, Anna S Husted, Jeppe P Ekberg, Michael J Wright, Jerry Di Salvo, Adam B Weinglass, Maja S Engelstoft, Andreas N Madsen, Michael Lückmann, Michael W Miller, Maria E Trujillo, Thomas M Frimurer, Birgitte Holst, Andrew D Howard, Thue W Schwart. GPR40 (FFAR1) - Combined Gs and Gq signaling in vitro is associated with robust incretin secretagogue action ex vivo and in vivo. Molecular metabolism. vol 4. issue 1. 2015-02-16. PMID:25685685. |
gpr40 (ffar1), a clinically proven anti-diabetes target, is a gq-coupled receptor for long chain fatty acids (lcfa) stimulating insulin secretion directly and mediating a major part of the dietary triglyceride-induced secretion of the incretins glp-1 and gip. |
2015-02-16 |
2023-08-13 |
Not clear |
| Kira B Harris, Delilah J McCart. Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus. Therapeutic advances in endocrinology and metabolism. vol 6. issue 1. 2015-02-14. PMID:25678952. |
all four glp-1 ras have demonstrated reductions in hemoglobin a1c, fasting blood glucose, and body weight both as monotherapy and in combination with first- and second-line diabetes agents including metformin, sulfonylureas, thiazolidinediones, and insulin. |
2015-02-14 |
2023-08-13 |
Not clear |
| Ryutaro Nakashima, Tatsuya Yano, Junko Ogawa, Naomi Tanaka, Narihiro Toda, Masao Yoshida, Rieko Takano, Masahiro Inoue, Takeshi Honda, Shoen Kume, Koji Matsumot. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists. European journal of pharmacology. vol 737. 2015-02-13. PMID:24858371. |
ds-1558 not only increased the glucose-stimulated insulin secretion by glp-1 but also potentiated the maximum insulinogenic effects of glp-1 after an intravenous glucose injection in normal sprague dawley rats. |
2015-02-13 |
2023-08-13 |
mouse |
| Laurie L Baggio, Daniel J Drucke. Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. The Journal of clinical investigation. vol 124. issue 10. 2015-02-09. PMID:25202976. |
the peptide hormone glucagon-like peptide-1 (glp-1) enhances glucose-induced insulin secretion and inhibits both gastric emptying and glucagon secretion. |
2015-02-09 |
2023-08-13 |
Not clear |
| R L O'Connor-Semmes, J Lin, R J Hodge, S Andrews, J Chism, A Choudhury, D J Nune. GSK2374697, a novel albumin-binding domain antibody (AlbudAb), extends systemic exposure of exendin-4: first study in humans--PK/PD and safety. Clinical pharmacology and therapeutics. vol 96. issue 6. 2015-01-30. PMID:25238251. |
postprandial glucose and insulin were reduced, and gastric emptying was delayed in healthy subjects, confirming anticipated glp-1 receptor agonist pharmacology. |
2015-01-30 |
2023-08-13 |
human |
| Marzieh Salehi, Amalia Gastaldelli, David A D'Alessi. Evidence from a single individual that increased plasma GLP-1 and GLP-1-stimulated insulin secretion after gastric bypass are independent of foregut exclusion. Diabetologia. vol 57. issue 7. 2015-01-29. PMID:24797288. |
evidence from a single individual that increased plasma glp-1 and glp-1-stimulated insulin secretion after gastric bypass are independent of foregut exclusion. |
2015-01-29 |
2023-08-13 |
Not clear |
| Derek J Nunez, Mark A Bush, David A Collins, Susan L McMullen, Dawn Gillmor, Glen Apseloff, George Atiee, Leonor Corsino, Linda Morrow, Paul L Feldma. Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies. PloS one. vol 9. issue 4. 2015-01-27. PMID:24699248. |
oral glucose and meal challenges were used to assess the effects on plasma glucose, insulin, c-peptide, glucagon, peptide tyrosine-tyrosine (pyy), glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic peptide (gip). |
2015-01-27 |
2023-08-13 |
human |
| T Dung Nguyen, Yasushige Shingu, Paulo A Amorim, Michael Schwarzer, Torsten Doens. Glucagon-like peptide-1 reduces contractile function and fails to boost glucose utilization in normal hearts in the presence of fatty acids. International journal of cardiology. vol 168. issue 4. 2015-01-26. PMID:23890859. |
glp-1 and exendin-4, which are used as insulin sensitizers or weight reducing drugs, were shown to improve glucose uptake in the heart. |
2015-01-26 |
2023-08-12 |
Not clear |
| Patricia López-Romero, Edgar Pichardo-Ontiveros, Azalia Avila-Nava, Natalia Vázquez-Manjarrez, Armando R Tovar, José Pedraza-Chaverri, Nimbe Torre. The effect of nopal (Opuntia ficus indica) on postprandial blood glucose, incretins, and antioxidant activity in Mexican patients with type 2 diabetes after consumption of two different composition breakfasts. Journal of the Academy of Nutrition and Dietetics. vol 114. issue 11. 2015-01-26. PMID:25132122. |
the purpose for conducting this study was to evaluate the glycemic index, insulinemic index, glucose-dependent insulinotropic peptide (gip) index, and the glucagon-like peptide 1 (glp-1) index, and the effect of nopal on patients with type 2 diabetes after consumption of a high-carbohydrate breakfast (hcb) or high-soy-protein breakfast (hspb) on the postprandial response of glucose, insulin, gip, glp-1, and antioxidant activity. |
2015-01-26 |
2023-08-13 |
human |
| K Yamashita, Y Sato, K Oki, H Kishimoto, K Yamauchi, T Aizaw. Marked improvement of insulin sensitivity without enhancement of GLP-1 and insulin secretion after Roux-en-Y gastric bypass surgery in a mildly obese patient with diabetes. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 46. issue 6. 2015-01-21. PMID:24526371. |
marked improvement of insulin sensitivity without enhancement of glp-1 and insulin secretion after roux-en-y gastric bypass surgery in a mildly obese patient with diabetes. |
2015-01-21 |
2023-08-12 |
Not clear |